Checkpoint inhibitors and next-generation TKIs have demonstrated improved survival outcomes in patients with non–small cell lung cancer (NSCLC); however, ongoing research efforts are looking to build upon the benefits with combination strategies and prevent acquired resistance to treatment, explained David P. Carbone, MD, PhD.
“It’s an incredibly exciting time in lung cancer. We have had 17 FDA approvals in the last 3 years, which is more than we have had in the last 30 years,” explained Carbone. “It’s becoming very complicated, but we’re seeing more long-term survivors and it’s very gratifying to see. It’s an exciting field to work in and I encourage more people to focus on lung cancer and help us look at this problem.” Read more.